{
    "organizations": [],
    "uuid": "f8f7691b7d5d1e88fc4aeca7b5c30d1099951f0e",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-valbiotis-completes-phase-i-ii-cli/brief-valbiotis-completes-phase-i-ii-clinical-study-recruitment-for-val-070-idUSFWN1QH19V",
    "ord_in_thread": 0,
    "title": "BRIEF-Valbiotis Completes Phase I/II Clinical Study Recruitment For VAL-070",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 27 (Reuters) - VALBIOTIS SAS:\n* VALBIOTIS COMPLETES PHASE I/II CLINICAL STUDY RECRUITMENT FOR VAL-070, A PRODUCT TO REDUCE A CARDIOVASCULAR RISK FACTOR\n* ‍CLINICAL SAFETY AND EFFICACY RESULTS ARE EXPECTED FOR MID-2018​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-02-28T00:39:00.000+02:00",
    "crawled": "2018-02-28T13:20:58.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "valbiotis",
        "sa",
        "valbiotis",
        "completes",
        "phase",
        "clinical",
        "study",
        "recruitment",
        "product",
        "reduce",
        "cardiovascular",
        "risk",
        "factor",
        "safety",
        "efficacy",
        "result",
        "expected",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}